xylyx

Drug response changes in the presence of ECM. Evaluate drug candidates in disease-relevant ECM settings IN MATRICO® that yield more predictive, in vivo-like results.

Related Resources

Application note: Accelerating anti-fibrotic drug development with human fibrotic liver ECM substrates
Application note: Accelerating anti-fibrotic drug development with human fibrotic lung ECM substrates
Application note: IN SITE™ Metastasis Kit to accelerate anticancer drug development
Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis
Poster: Fibrotic liver extracellular matrix substrates for 3D in-vitro models of human liver fibrosis
Poster: Fibrotic lung extracellular matrix substrates for 3D in-vitro models of human pulmonary fibrosis
Poster: TissueSpec® Bone, Liver, and Lung ECM substrates enable disease-relevant in-vitro models of pre-metastatic tissue microenvironments.
Poster: TissueSpec® ECM Hydrogels for predictive 3D models of human cancer
Webinar: Redefining cancer research with IN SITE™ Metastasis Kit
Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform